Vanda Pharmaceuticals Inc.
For the period ended Dec 30, 2025. Filed Dec 31, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Dec 30, 2025 · Filed Dec 31, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · About NEREUS™
About NEREUS™
NEREUS™ (tradipitant) is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. NEREUS™ is approved for the acute prevention of vomiting induced by motion in adults, and is currently in clinical development for a variety of indications, including gastroparesis and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.